STAT!Ref Supplemental Updates

ACP PIER & AHFS DI® Essentials™ ©2009
©2009 ACP PIER: American College of Physicians
©2009 AHFS DI® Essentials™
Authors/Editors: ACP PIER: American College of Physicians (ACP) © 2009 by the American College of Physicians
PIER© is a collection of over 490 evidence summaries published by the American College of Physicians. Each module provides authoritative guidance to improve the quality of care. Important features of PIER include:
•Truly evidenced-based
•Defines the current standard of care
•Frequently updated (Monthly Content Updates and Module Additions)
•Consistently structured for rapid access
•Search or browse by organ system
•Integrated drug reference (AHFS DI Essentials)
Topics are selected by ACP based upon prevalence in clinical settings. Evidence is then gathered by literature review and evaluated based on formal criteria. The level of evidence for each recommendation is displayed clearly within the application. PIER also includes topics in complementary and alternative medicine, ethical and legal issues, and procedures. Pediatric modules are now included.
AHFS DI® Essentials™ by the American Society of Health-System Pharmacists® (ASHP) is designed to offer health professionals easy access to knowledge that is critical at the point of care. Essentials™ monographs draw on the meticulously evidence-based guidelines in the full AHFS DI® database, distilling for the health professional the essential information on prescription and key over-the-counter (OTC) drugs in an easy-to-use, highly structured outline format.
•Comparative pricing for most Rx and OTC monographs.
•'Compatibility' sub-heading under the ‘Stability’ section within a monograph features Admixture and Y-Site and is perfect for nurses who administer drugs.
•Essentials™ includes a subset of drugs from the full AHFS DI® database. Drugs were selected from those most widely used in hospital (including most parenteral drugs) and outpatient (including key OTC products) settings, new molecular entities (NMEs) introduced into the US market over the past 6 years, and drugs requiring particular attention for safe use (e.g., those with boxed warnings).
What's New in October 2009
UPDATED MODULES:
Advance Care Planning
Arterial Blood Gases
Asthma in Pregnancy
Autoimmune Hepatitis Carotid
Artery Stenosis
Chronic Fatigue Syndrome
Chronic Pancreatitis
Electrocardiogram
Esophageal Cancer
Fibromyalgia Syndrome
Hemophilia
Hepatitis A
Hepatitis B
Hypercalcemia
LASIK Eye Surgery
Lipid Disorders (Dyslipidemia)
Nodular Thyroid Disease
Osteoarthritis
Parvovirus B19 Infection and Fifth Disease
Perioperative Evaluation of Patients with Liver Disease
Pleurisy
Preoperative Cardiac Risk Assessment
Prevention of Unintended Pregnancy
Rosacea
Salicylate Poisoning Screening for Lung Cancer
Systemic Lupus Erythematosus
Vulvar Cancer
Vulvodynia (Vulvar Pain)

ACP PIER, Journal Club & AHFS DI® Essentials™
©2009 by the American College of Physicians
Authors/Editors: American College of Physicians (ACP)
A pre-appraised, evidence-based clinical tool that defines the standard of care, including value-added abstracts of original journal articles and drug treatment information.
PIER (Physicians' Information and Education Resource)
•Integrated and authoritative EBM resources for the point-of-care and background reference.
•Links in PIER's disease modules take users to supporting articles in ACPJC.
•Updated Monthly
•Combined with AHFS Essentials, the drug resource that provides quick access to dosage, interaction and other pharmacy information.
ACPJC
•ACP Journal Club is the quintessential EBM journal that summarizes original research applicable to clinical cases.
•Over 100 journals are reviewed for implications on therapeutics, diagnosis, prognosis and etiology.
•McMaster Online Rating of Evidence (MORE) gathers ratings of new articles, already assessed for scientific merit, from sentinel readers (a panel of 2000+ physicians from around the world).
AHFS® DI Essentials™
•Distills the essential information from the larger AHFS Drug Information database.
•Comparative pricing for most Rx and OTC monographs.

©2009 by the American Society of Health-System Pharmacists, Inc.
Authors/Editors: Gerald K. McEvoy, Pharm.D.
AHFS DI® Essentials™ offers healthcare professionals easy access to knowledge that is critical at the point of care. Essentials™ monographs draw on the meticulously evidence-based guidelines in the full AHFS DI® database, distilling essential information on prescription and key over-the-counter (OTC) drugs in an easy-to-use and highly structured outline format.
Comparative pricing for most Rx and OTC monographs.
What's New in November 2009:
New Monographs:
- Polymyxin B Antibacterial; polymyxin antibiotic structurally and pharmacologically related to colistin.
Revised Monographs:
- Amantadine: Antiviral; antiparkinsonian agent; adamantane derivative.
- Cefazolin: Antibacterial; b-lactam antibiotic; first generation cephalosporin.
- Cefotetan: Antibacterial; b-lactam antibiotic; cephamycin.
- Ceftriaxone: Antibacterial; b-lactam antibiotic; third generation cephalosporin.
- Emtricitabine: Antiretroviral; nucleoside reverse transcriptase inhibitor (NRTI).
- Entecavir: Antiviral; purine nucleoside analog derived from guanine.
- Etravirine: Antiretroviral; nonnucleoside reverse transcriptase inhibitor (NNRTI).
- Exenatide: Antidiabetic agent; synthetic glucagon-like peptide-1 (GLP-1) mimetic (incretin mimetic).
- Ezetimibe: Antilipemic agent; cholesterol absorption inhibitor.
- Heparin: Anticoagulant; a heterogeneous group of anionic, sulfated glycosaminoglycans.
- Iron Dextran: Ferric hydroxide in a complex with partially hydrolyzed low molecular weight dextran.
- Omeprazole: Acid- or proton-pump inhibitor; gastric antisecretory agent.
- Oseltamivir: Antiviral; neuraminidase inhibitor; sialic acid analog.
- Pantoprazole: Acid- or proton-pump inhibitor; gastric antisecretory agent.
- Raltegravir: Antiretroviral; HIV integrase inhibitor.
- Rimantadine: Antiviral; adamantane derivative.
- Rituximab: Antineoplastic agent; a chimeric human-murine anti-human antigen CD20 monoclonal antibody.
- Simvastatin: Antilipemic agent; hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor (i.e., statin).
- Zanamivir: Antiviral; neuraminidase inhibitor; sialic acid analog.

©2009 American Society of Health-System Pharmacists
Authors/Editors: Gerald K. McEvoy, Pharm.D. and Elaine K. Snow, B.S. Pharm.
With the 2009 edition, the American Hospital Formulary Service® (AHFS™) marks over 50 years of continuous publication by the American Society of Health-System Pharmacists (ASHP). Each year, an average of over 60% of AHFS content is revised to help you provide the most accurate recommendations for your patients’ drug therapy. AHFS references are evidence-based and peer-reviewed, compiled without the influence of manufacturers, insurers, regulators or other interested parties. No other drug information sources can make this claim. AHFS DI has been designated as an official compendium by the US Congress. AHFS DI contains information from medical literature and expert advice from over 500 medical scientists, physicians, pharmacists, pharmacologists and other professionally qualified individuals that goes beyond FDA-approved labeling.
What's New in November 2009-Revised Monographs:
- Amantadine
- Antihistamines General Statement
- Antiretroviral Agents General Statement
- Cefazolin
- Cefotetan
- Cefoxitin
- Ceftriaxone
- Emtricitabine
- Entecavir
- Etravirine
- Exenatide
- Heparin
- Iron Dextran
- Omeprazole
- Oseltamivir
- Pantoprazole
- Polymyxin B
- Promethazine
- Raltegravir
- Rimantadine
- Rituximab
- Tetracyclines General Statement
- Zanamivir

©2009 American Pharmacists Association (APhA)
Authors/Editors: L. Michael Posey
APhA DrugInfoLine® is a monthly newsletter of interpreted drug and pharmacotherapeutic information designed to keep frontline pharmacists current on the latest trends in the biomedical literature.
It includes regular coverage of these areas:
• Cardiology • Psychiatry • HIV Care • Endocrinology • Pulmonology • Immunizations • Gastroenterology • Rheumatology • Lipids Management • Infectious Diseases • Anticoagulation Care • Alternative Medicines • Neurology • Asthma Care • OTC Medications • Oncology • Diabetes Care • Drug Interactions
Each issue includes a "Medication Monitor," a table that summarizes new drug approvals.
What's New: September/October 2009, Vol. 10, No. 9/10
- Focus On: HIV Care - Betty J. Dong, Section Advisor
- Focus On: Immunizations - John D. Grabenstein, Section Advisor
- Drug Interactions Corner - Daniel S. Streetman, Section Advisor
- Psychiatric Disorders - M. Lynn Crismon, Section Advisor
- Focus On: Asthma Care - Devra K. Dang, Section Advisor
- Cardiovascular Disorders - Omar Badawi, Section Advisor
- Gastroenterologic Disorders - C. Wayne Weart, Section Advisor
- Alternative Medicines Corner - Nicole M. Maisch, Section Advisor
- Medication Monitor: Updates On Advances In Therapy













Entamoeba histolytica trophozoite, trichrome stain